Abstract
dc:description.abstractProcesses leading to the <i>in vitro</i> activation of progelatinase-A, progelatinase-B and procollagenase were examined. Progelatinase-A can be activated by treatment with 4-aminophenyl mercuric acetate or by matrilysin and collagenase. The former induces an intramolecular self-cleavage before further intermolecular cleavages generate the mature enzyme. Whilst matrilysin can process progelatinase-A to the mature form, collagenase can only generate an intermediate by cleaving after N<sub>37</sub> in the bait region. This intermediate is identical to that produced by a human tumour cell-line in culture. Gelatinase-A reciprocates the action of collagenase by completing the activation of the latter to generate a form of collagenase with full collagenolytic activity. This has been described as superactivation and is commonly associated with the action of stromelysin. It correlates with the appearance of F<sub>81</sub> at the amino-terminus. <br></br><br></br> The C-terminal domain plays no role in catalysis but may be important for <i>in vivo</i> activity. This is particularly evident for collagenase which loses the ability to cleave collagen in its absence. The interaction between collagenase and collagen was shown to be a potential target for designing inhibitors of collagen breakdown. <br></br><br></br> The properties of a series of reversible, competitive hydroxamic acid matrix metalloproteinase inhibitors were studied. Incorporation of a phenylpropyi group in the P<sub>1</sub>' position produced inhibitors with picomolar affinities for the gelatinases and discriminated against collagenase and matrilysin and other classes of zinc metallopeptidases. The high affinity of these inhibitors for gelatinase-A was shown to derive from a combination of diffusion limited association rates and very slow dissociation rates. <br></br><br></br> Methods were developed to allow the study of the pharmacokinetic properties of these inhibitors. Chemical modifications at the P<sub>2</sub>’ and P<sub>3</sub>’ positions were shown to result in inhibitors with oral bioavailabilities of greater than 30% in the mouse.
Degree
thesis:*- Name dc:type.qualificationname
- phd
- Level dc:type.qualificationlevel
- doctoral
- Grantor dc:publisher.institution
- The Open University
- Year dc:date.issued
- 1995
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- O'Connell, James Philip
Rights
- Language dc:language
- en